Accelerating hit finding programs: Echo MS and RapidFire-MS key advantages
The goal of drug discovery programs for small molecule developments is clear: to identify the most promising hits and leads with “drug-like” properties in the shortest time. Successful preclinical candidates are ultimately selected by employing robust hit finding strategies, which combine relevant and innovative assays with reproducible, miniaturized and reliable in vitro tests.
Specifically, we outline how Eurofins Discovery:
Integrated the Echo®️ MS into our labs and explored and validated its capabilities
Ran a High Throughput Screening (HTS) Proof of Concept on this new platform
Determines which Mass Spectrometry (MS) method is most appropriate for a particular target or endpoint
Has established a portfolio of services based on complementary biophysical technologies to provide state-of-the-art hit confirmation approaches.